EVALI versus MIS-C, one more overlapping diagnosis to consider
Diego A Cruz-Vidal, MD1, Eric S Mull, DO2, Jeanette Taveras, DO1, Richard Shell, MD2, Garrett W. Hunt, MD1, Brain Fowler, BA1, Rebecca Wallihan, MD1, Guliz Erdem, MD1
Affiliations : 1Division of Infectious Diseases, Nationwide Children’s Hospital, Columbus, Ohio,2Division of Pulmonary Medicine, Nationwide Children’s Hospital, Columbus, Ohio
Address correspondence to : Guliz Erdem, Division of Infectious Diseases, Nationwide Children’s Hospital, 700 Children’s drive, Columbus, OH, 43205, [Guliz.Erdem@nationwidechildrens.org], 614-722-8925
Short title: EVALI versus MIS-C
Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article to disclose
Funding/Support : No funding was secured for this study.
Abbreviations :
MIS-C: multisystem inflammatory syndrome in children; EVALI: E-cigarette, or vaping, product use-associated lung injury; COVID-19: Coronavirus disease 2019; CDC: Centers for Disease Prevention and Control; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; PCT: Procalcitonin; LDH: Lactate Dehydrogenase; NP: Nasopharyngeal; FRVP: FilmArray® respiratory panel; THC: tetrahydrocannabinol; CT: Computerized tomography; BAL: Bronchoalveolar Lavage
Summary :
We describe 6 teenagers with suspected MIS-C in which EVALI was the final diagnosis; we emphasis the importance of including EVALI as a differential diagnosis.